Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older. But late Friday, the FDA granted ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

FDA Approves Novavax COVID-19 Shot but With Unusual Restrictions WASHINGTON (AP) — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with ...